Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.36 AUD | +1.27% | +5.05% | -10.25% |
Mar. 14 | Clinuvel Pharmaceuticals Launches Share Buyback Program | MT |
Mar. 14 | Morgans Financial Upgrades Clinuvel Pharmaceuticals to Add From Hold; Price Target is AU$16 | MT |
Sales 2024 * | 89.47M 58.22M | Sales 2025 * | 101M 65.89M | Capitalization | 711M 463M |
---|---|---|---|---|---|
Net income 2024 * | 34M 22.12M | Net income 2025 * | 37M 24.08M | EV / Sales 2024 * | 5.86 x |
Net cash position 2024 * | 187M 122M | Net cash position 2025 * | 216M 140M | EV / Sales 2025 * | 4.89 x |
P/E ratio 2024 * |
20.9
x | P/E ratio 2025 * |
19.2
x | Employees | - |
Yield 2024 * |
0.48% | Yield 2025 * |
0.52% | Free-Float | 79.56% |
Latest transcript on Clinuvel Pharmaceuticals Limited
1 day | +1.27% | ||
1 week | +1.48% | ||
Current month | +4.97% | ||
1 month | +1.70% | ||
3 months | -11.14% | ||
6 months | -3.62% | ||
Current year | -10.25% |
Managers | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Darren M. Keamy
DFI | Director of Finance/CFO | - | 05-10-31 |
Lachlan Hay
COO | Chief Operating Officer | - | 06-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philippe Wolgen
CEO | Chief Executive Officer | 61 | 05-10-31 |
Director/Board Member | - | 07-02-05 | |
Karen Agersborg
BRD | Director/Board Member | - | 18-01-28 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 14.36 | +1.27% | 84 624 |
24-03-27 | 14.18 | +3.13% | 81,515 |
24-03-26 | 13.75 | +0.73% | 111,836 |
24-03-25 | 13.65 | -1.09% | 87,416 |
24-03-22 | 13.8 | -2.47% | 90,057 |
Delayed Quote Australian S.E., March 28, 2024 at 01:10 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.25% | 464M | |
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.40% | 31.45B | |
+43.60% | 23.35B | |
-8.10% | 16.72B | |
-25.64% | 15.09B | |
-9.03% | 12.82B | |
-9.37% | 11.95B | |
+98.58% | 7.67B |